| 1 |
Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data |
|
| | MohammedAyaz Khan, Nahed Sherbini, Sami Alyami, Abdullah Al-Harbi, Majed Al-Ghamdi, Suliman Alrajhi, Rajkumar Rajendram, Hamdan Al-Jahdali | | | Annals of Thoracic Medicine. 2023; 18(1): 45 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Impacto de la rehabilitación pulmonar en pacientes con enfermedad pulmonar restrictiva |
|
| | J. Betancourt-Peña, J.A. Rivera, L.M. Orozco, N. Torres-del Castillo, V. Benadives-Córdoba | | | Fisioterapia. 2022; | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Physical activity, exercise capacity and mortality risk in people with interstitial lung disease: a systematic review and meta-analysis |
|
| | Vânia Rocha, Cátia Paixão, Alda Marques | | | Journal of Science and Medicine in Sport. 2022; | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
Clinical characteristics and outcomes in patients with primary Sjogren's syndrome-associated interstitial lung disease |
|
| | EsamH Alhamad, JosephG Cal, NuhaN Alrajhi, MuthurajanP Paramasivam, WaleedM Alharbi, Mohammed AlEssa, MohammedA Omair, AmmarC AlRikabi, AhmadA AlBoukai | | | Annals of Thoracic Medicine. 2021; 16(2): 156 | | | [Pubmed] [Google Scholar] [DOI] | | | 5 |
Predictors of Mortality in Patients with Interstitial Lung Disease-Associated Pulmonary Hypertension |
|
| | Esam H. Alhamad, Joseph G. Cal, Nuha N. Alrajhi, Waleed M. Alharbi | | | Journal of Clinical Medicine. 2020; 9(12): 3828 | | | [Pubmed] [Google Scholar] [DOI] | |
|
